NASDAQ$WVE
Wave Life Sciences Ltd · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Wave Life Sciences announced Q3 2021 financial results and provided a business update.
Wave Life Sciences reported a net loss of $6.2 million for the third quarter of 2021, with revenue of $36.4 million. The company highlighted advancements in its RNA editing capabilities and the initiation of dosing in three clinical trials.
- Strengthened balance sheet with approximately $52 million.
- Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic threshold.
- Dosing ongoing in three clinical programs (WVE-004, WVE-003, WVE-N531); data being generated through 2022 to enable decision-making.
- Wave expects to share additional ADAR editing data using AIMers in scientific publications and presentations in 2022.
Headline financials
Revenue & EPS history
Wave Life Sciences · Revenue · Quarterly
$36.4M
Forward guidance
Wave expects that its existing cash and cash equivalents will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.9%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+8.2%
Avg return
30 days after
48%
20 / 42 earnings
Positive
+42.4%
Q4 2023
Best reaction
-16.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.4% | +5.3% | -6.9% | |
| Q4 2025 | +5.6% | -7.6% | -56.2% | |
| Q3 2025 | -10.3% | -9.9% | +157.4% | |
| Q1 2025 | +0.5% | -1.5% | +11.2% | |
| Q4 2024 | +11.7% | -6.5% | -33.9% | |
| Q3 2024 | -4.6% | -16.8% | -15.8% | |
| Q2 2024 | -9.5% | -6.9% | -14.2% | |
| Q1 2024 | -3.9% | -0.2% | -0.7% | |
| Q4 2023 | +42.4% | +42.0% | +23.4% | |
| Q3 2023 | -8.9% | -5.6% | -21.7% | |
| Q2 2023 | +14.4% | +3.0% | +3.9% | |
| Q1 2023 | -0.8% | +8.2% | +23.6% | |
| Q4 2022 | -11.1% | -11.8% | +1.9% | |
| Q3 2022 | -7.6% | -19.3% | -1.3% | |
| Q2 2022 | +37.3% | +45.1% | +26.7% | |
| Q1 2022 | -16.3% | -13.6% | +46.3% | |
| Q4 2021 | -5.7% | -17.1% | -17.5% | |
| Q3 2021 | +1.5% | -3.2% | -25.7% | |
| Q2 2021 | +7.0% | -0.4% | +12.3% | |
| Q1 2021 | +1.5% | +9.6% | +18.3% | |
| Q4 2020 | -7.8% | -8.9% | -40.5% | |
| Q3 2020 | +2.8% | +11.9% | +19.3% | |
| Q2 2020 | +1.5% | -0.5% | +36.9% | |
| Q1 2020 | +28.2% | +30.2% | +28.1% | |
| Q4 2019 | -3.2% | +9.8% | +6.6% | |
| Q3 2019 | -1.0% | +3.1% | +20.9% | |
| Q2 2019 | -3.4% | -9.4% | +3.1% | |
| Q1 2019 | -0.8% | -1.0% | -10.7% | |
| Q4 2018 | +6.1% | +7.6% | -7.3% | |
| Q3 2018 | -12.3% | -15.3% | +4.4% | |
| Q2 2018 | +10.7% | +16.4% | +25.7% | |
| Q1 2018 | -6.9% | -9.7% | +11.5% | |
| Q4 2017 | -7.9% | -11.7% | -10.5% | |
| Q3 2017 | +3.2% | +12.0% | +66.5% | |
| Q2 2017 | -7.7% | -12.8% | +18.4% | |
| Q1 2017 | +2.6% | +7.9% | -2.2% | |
| Q4 2016 | -2.0% | -4.4% | -14.8% | |
| Q3 2016 | +15.3% | +18.2% | +5.2% | |
| Q2 2016 | +5.7% | +13.5% | +26.9% | |
| Q1 2016 | -2.7% | — | — | |
| Q4 2015 | -3.1% | — | — | |
| Q3 2015 | +11.1% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro